Syros Pharmaceuticals, Inc. (SYRS)
| Market Cap | 329.40M |
| Revenue (ttm) | 17.54M |
| Net Income (ttm) | -81.04M |
| Shares Out | 61.38M |
| EPS (ttm) | -1.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $5.22 |
| Previous Close | $5.09 |
| Change ($) | 0.13 |
| Change (%) | 2.55% |
| Day's Open | 5.18 |
| Day's Range | 5.13 - 5.42 |
| Day's Volume | 1,109,270 |
| 52-Week Range | 4.75 - 15.65 |
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 58.18% and 58.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
Syros Pharmaceuticals, Inc. (SYRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str...
Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuti...
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -12.96% and 78.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter an...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that members of its management team...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expecte...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39TH ANNUAL J.P. MORGAN HE...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...
Syros Pharmaceuticals doubled its stock price in 2020. Syros recently acquired SY-2101 from Orsenix.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously ann...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...
Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical d...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (P...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data f...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S.
Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2020 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 5.00% and 45.57%, respectively, for the quarter ended June 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, J...
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
Top Ranked Momentum Stocks to Buy for May 19th
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2020 Results - Earnings Call Transcript
Syros Pharmaceuticals Inc (SYRS) delivered earnings and revenue surprises of 13.33% and 38.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) were unchanged in pre-market trading after the company reported Q1 results.
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Syros, Beyond Oncology
Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q4 2019 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.13% and -35.53%, respectively, for the quarter ended December 2019.
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Syros Pharmaceuticals Update: Still A Buy
As of late, it has definitely been a great time to be an investor Syros Pharmaceuticals
Investors appeared to like the addition of a well-known new board member.
Syros Pharmaceuticals (SYRS) news for Wednesday about plans for developing new drugs and a $20 million payment have SYRS stock flying high.
Global Blood Therapeutics Inc. and Syros Pharmaceuticals announced a partnership to develop and commercialize therapies for sickle cell disease and beta thalassemia.
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.
Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2019 Results - Earnings Call Transcript
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial ... [Read more...]
| Industry Biotechnology | IPO Date Jun 30, 2016 |
| CEO Nancy Simonian | Employees 103 |
| Stock Exchange NASDAQ | Ticker Symbol SYRS |
Financial Performance
In 2020, SYRS's revenue was $15.09 million, an increase of 661.50% compared to the previous year's $1.98 million. Losses were -$84.04 million, 11.4% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 16.57, which is an increase of 217.43% from the latest price.